Mydecine Innovations Group (NVRS) Stock Statistics & Valuation Metrics

Mydecine Innovations Group has a market cap or net worth of CAD 2.63M. The enterprise value is CAD 73.33M.

Market Cap

CAD 2.63M

Enterprise Value

CAD 73.33M

Mydecine Innovations Group has 58,548,050 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

58,548,050

Owned by Insiders

1.96%

Owned by Institutions

<0.01%

Mydecine Innovations Group’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

Return on Equity (ROE)

―

Return on Assets (ROA)

―

Return on Invested Capital (ROIC)

―

Return on Capital Employed (ROCE)

―

Revenue Per Employee

―

Profits Per Employee

-4.45M

Employee Count

3

Asset Turnover

―

Inventory Turnover

―

In the last 12 months, Mydecine Innovations Group had revenue of ― and earned -13.36M in profits. Earnings per share was ―.

Revenue

―

Gross Profit

97.83K

Operating Income

-5.81M

Pretax Income

―

Net Income

-13.36M

EBITDA

-13.26M

Earnings Per Share (EPS)

―

Beta

-11.35

52-Week Price Change

-75.00%

50-Day Moving Average

0.09

200-Day Moving Average

0.99

Relative Strength Index (RSI)

26.46

Average Volume (3m)

596.90K

Mydecine Innovations Group upcoming earnings date is Nov 17, 2026, TBA (Not Confirmed).

Last Earnings Date

Aug 31, 2026

Next Earnings Date

Nov 17, 2026

Ex-Dividend Date

―

Mydecine Innovations Group has ― in cash and marketable securities with CAD 4.88M in debt, giving a net cash position of ― billion.

Cash & Marketable Securities

―

Total Debt

CAD 4.88M

Net Cash

―

Net Cash Per Share

―

Tangible Book Value Per Share

―

The average price target for Mydecine Innovations Group is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target

―

Price Target Upside

―

Analyst Consensus

―

Analyst Count

0

Revenue Growth Forecast

―

EPS Growth Forecast

1309.52%